BRAF and Sepsis: Two patients discontinued treatment due to side effects: In patient 26 (PCP with BRAF V600E mutation) therapy with dabrafenib/trametinib was discontinued after three months despite a partial response on MRI because of three episodes of fever, some of which were sepsis-like (CTCAE grade 4) (Fig. 5B).